Novo Nordisk Halts Two Additional Heart Drug Trials
On September 7, 2026, Novo Nordisk A/S (NYSE:NVO) announced the early termination of two additional trials for its experimental cardiovascular drug ziltivekimab. An independent data monitoring committee concluded that these heart-failure studies were unlikely to yield different results from a previously failed late-stage trial in reducing major adverse cardiovascular events. Despite this setback, Novo Nordisk will continue testing ziltivekimab in patients recovering from a heart attack, with results expected by mid-2027. A positive outcome could provide the company another growth opportunity outside its dominant obesity and diabetes segment. The decision to halt trials allows for resource reallocation toward higher-potential programs. The move weakens Novo's diversification strategy in cardiovascular care and increases reliance on its core GLP-1 business, particularly with Wegovy’s strong performance post-launch. Competitive pressure from Eli Lilly remains a concern as the company faces greater challenges to sustain growth within its primary therapeutic area.
Tickers: $NVO
Topics: cardiovascular drugs clinical trials drug development ziltivekimab